Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Psoriasis: HELP
Stefania Padula
Based on 4 articles published since 2008
||||
Expertise Level

  What is this?

Expertscape's algorithms degrade at low publication numbers. Thus, with only 4 published articles on Psoriasis from 2008 through 2019, it is not possible for Expertscape to reliably rate Stefania Padula's expertise on this topic.

Uncounted papers?
Aliases Padula, Steven J   ·   Padula, Stefania   ·   Padula, Steven
Work Locations
Details
Most likely:    Boehringer Ingelheim      
2019
  • Sorbonne Paris Cité Université Paris Diderot, Paris, France · Monash University Malaysia, Johor Bahru, Malaysia. · Hedi Chaker University Hospital, Sfax, Tunisia. · University of Glasgow, Glasgow, United Kingdom. · National Taiwan University, Taipei, Taiwan. · Nagoya City University, Nagoya, Japan. · Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT. · Boehringer Ingelheim International, Biberach, Germany. · Boehringer Ingelheim International, Ingelheim, Germany. · Pubmed 30855749
2017
  • From K. Papp Clinical Research and Probity Medical Research, Waterloo, ON (K.A.P.), School of Medicine, Queen's University, Kingston, ON (M.G.), and Centre for Dermatology and Probity Medical Research, Peterborough, ON (M.G.) - all in Canada · Oregon Medical Research Center, Portland (A.B.) · Altman Dermatology Associates, Arlington Heights, IL (M.B.) · Rockefeller University, New York (J.K.) · Hôpital de l'Archet, University of Nice-Sophia Antipolis, Nice, France (J.-P.L.) · Baylor Research Institute, Dallas (A.M.) · Charité Universitätsmedizin Berlin, Berlin (S.P.), Boehringer Ingelheim Pharma, Biberach (B.R.B.), and Boehringer Ingelheim Pharma, Ingelheim, (S.J.P.) - all in Germany · University of Texas Health Science Center, Houston (S.T.) · University of California, Los Angeles, School of Medicine, Los Angeles (H.S.) · and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.V., C.P., N.B., M.F., P.S.). · Pubmed 28423301
2015
  • Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. Electronic address: · UPMC Department of Dermatology, Pittsburgh, Pa. · Baylor Research Institute, Dallas, Tex. · Charité Research Organization, Berlin, Germany. · Progressive Medical Research, Port Orange, Fla. · Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Conn. · Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. · Pubmed 25769911
Probable:    Charite-Universitatsmedizin      
2017
  • From K. Papp Clinical Research and Probity Medical Research, Waterloo, ON (K.A.P.), School of Medicine, Queen's University, Kingston, ON (M.G.), and Centre for Dermatology and Probity Medical Research, Peterborough, ON (M.G.) - all in Canada · Oregon Medical Research Center, Portland (A.B.) · Altman Dermatology Associates, Arlington Heights, IL (M.B.) · Rockefeller University, New York (J.K.) · Hôpital de l'Archet, University of Nice-Sophia Antipolis, Nice, France (J.-P.L.) · Baylor Research Institute, Dallas (A.M.) · Charité Universitätsmedizin Berlin, Berlin (S.P.), Boehringer Ingelheim Pharma, Biberach (B.R.B.), and Boehringer Ingelheim Pharma, Ingelheim, (S.J.P.) - all in Germany · University of Texas Health Science Center, Houston (S.T.) · University of California, Los Angeles, School of Medicine, Los Angeles (H.S.) · and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.V., C.P., N.B., M.F., P.S.). · Pubmed 28423301
Possible:    University of Naples Federico II      
2010
  • Department of Clinical and Experimental Medicine, Early Psoriatic Arthritis Clinic, University Federico II, Naples, Italy. · Pubmed 20066450
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of all articles written by Stefania Padula in 2008-2019 about Psoriasis:

  • Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. 2019
  • Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. 2017
  • Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. 2015
  • Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. 2010
Show List of Full Article Records
Google Searches

Learn more about Stefania Padula using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Boehringer Ingelheim
Charite-Universitatsmedizin
University of Naples Federico II
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Boehringer Ingelheim
2019
  • Sorbonne Paris Cité Université Paris Diderot, Paris, France · Monash University Malaysia, Johor Bahru, Malaysia. · Hedi Chaker University Hospital, Sfax, Tunisia. · University of Glasgow, Glasgow, United Kingdom. · National Taiwan University, Taipei, Taiwan. · Nagoya City University, Nagoya, Japan. · Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT. · Boehringer Ingelheim International, Biberach, Germany. · Boehringer Ingelheim International, Ingelheim, Germany. · Pubmed 30855749
2017
  • From K. Papp Clinical Research and Probity Medical Research, Waterloo, ON (K.A.P.), School of Medicine, Queen's University, Kingston, ON (M.G.), and Centre for Dermatology and Probity Medical Research, Peterborough, ON (M.G.) - all in Canada · Oregon Medical Research Center, Portland (A.B.) · Altman Dermatology Associates, Arlington Heights, IL (M.B.) · Rockefeller University, New York (J.K.) · Hôpital de l'Archet, University of Nice-Sophia Antipolis, Nice, France (J.-P.L.) · Baylor Research Institute, Dallas (A.M.) · Charité Universitätsmedizin Berlin, Berlin (S.P.), Boehringer Ingelheim Pharma, Biberach (B.R.B.), and Boehringer Ingelheim Pharma, Ingelheim, (S.J.P.) - all in Germany · University of Texas Health Science Center, Houston (S.T.) · University of California, Los Angeles, School of Medicine, Los Angeles (H.S.) · and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.V., C.P., N.B., M.F., P.S.). · Pubmed 28423301
2015
  • Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. Electronic address: · UPMC Department of Dermatology, Pittsburgh, Pa. · Baylor Research Institute, Dallas, Tex. · Charité Research Organization, Berlin, Germany. · Progressive Medical Research, Port Orange, Fla. · Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Conn. · Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. · Pubmed 25769911
Charite-Universitatsmedizin
2017
  • From K. Papp Clinical Research and Probity Medical Research, Waterloo, ON (K.A.P.), School of Medicine, Queen's University, Kingston, ON (M.G.), and Centre for Dermatology and Probity Medical Research, Peterborough, ON (M.G.) - all in Canada · Oregon Medical Research Center, Portland (A.B.) · Altman Dermatology Associates, Arlington Heights, IL (M.B.) · Rockefeller University, New York (J.K.) · Hôpital de l'Archet, University of Nice-Sophia Antipolis, Nice, France (J.-P.L.) · Baylor Research Institute, Dallas (A.M.) · Charité Universitätsmedizin Berlin, Berlin (S.P.), Boehringer Ingelheim Pharma, Biberach (B.R.B.), and Boehringer Ingelheim Pharma, Ingelheim, (S.J.P.) - all in Germany · University of Texas Health Science Center, Houston (S.T.) · University of California, Los Angeles, School of Medicine, Los Angeles (H.S.) · and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.V., C.P., N.B., M.F., P.S.). · Pubmed 28423301
University of Naples Federico II
2010
  • Department of Clinical and Experimental Medicine, Early Psoriatic Arthritis Clinic, University Federico II, Naples, Italy. · Pubmed 20066450
Yearly article counts 101010000100
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.